Standard BioTools Inc. Common Stock
LABStandard BioTools Inc. (LAB) is a provider of laboratory instruments, software, and consumables used in life science research and diagnostics. The company specializes in enabling scientific and clinical discoveries through its innovative solutions for genomics, proteomics, and cell analysis, supporting pharmaceutical, biotech, and academic research communities.
Company News
Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties to shareholders. The investigations concern AstroNova (being acquired by Arcline for $29.00/share), Open Lending (being acquired by ANV Group for $3.15/share), Huntsman (merging with Olin in a stock exchange), and Stand...
Standard BioTools (NASDAQ:LAB) and Treeline Biosciences announced a definitive merger agreement to combine in an all-stock transaction. The combined company will operate as Treeline Biosciences under ticker 'TRLN' and will be led by Treeline CEO Josh Bilenker. The merger is expected to close in the second half of 2026, with the combined entity ha...
Standard BioTools Inc. (NASDAQ: LAB) announced it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U.S. market close. The company is a leading provider of mass cytometry and microfluidics technologies for biomedical research.
Standard BioTools Inc. (NASDAQ: LAB) announced it will release its fourth quarter and full year 2025 financial results on February 24, 2026. The company also completed the sale of SomaLogic to Illumina for $350 million upfront with up to $425 million in total proceeds, leaving the company with approximately $550 million in cash and cash equivalen...
Standard BioTools will report its second quarter 2025 financial results on August 11, 2025, hosting a conference call at 4:30 p.m. ET to discuss financial performance and operational progress.
